SAN JOSE, Calif., Sept. 28, 2018 /PRNewswire/ -- ITUS
Corporation (the "Company") (NASDAQ: ITUS), a biotechnology company
focused on using the body's immune system to fight cancer, today
announced that on October 1, 2018,
the Company will officially change its name to Anixa Biosciences,
Inc. Effective at the start of trading on October 1, 2018, the Company's shares will trade
on the NASDAQ Capital Market under the new name, and the new stock
symbol will be "ANIX." The Company's website will be
accessible at www.anixa.com.
Amit Kumar, the Company's CEO
stated, "We are focused on making advances in the biotechnology
field. We began in diagnostics with development of the
Cchek™ platform for early detection of cancer and are
expanding into cancer therapeutics as we develop our CAR-T therapy
for ovarian cancer. We believe the name Anixa Biosciences
more accurately reflects this focus and clearly identifies us as
biotech company. The ITUS name is more reflective of our
legacy operations."
ITUS Corporation
ITUS, a cancer-focused biotechnology
company, is harnessing the body's immune system in the fight
against cancer. ITUS is developing both diagnostics and
therapeutics to detect cancer early, when it is most curable, and
to treat those afflicted once diagnosed. It is developing the
Cchek™ platform, a series of inexpensive non-invasive
blood tests for the early detection of solid tumors, which is based
on the body's immune response to the presence of a
malignancy. It is also developing chimeric antigen receptor
T-cell (CAR-T) based immuno-therapy drugs which genetically
engineer a patient's own immune cells to fight cancer. ITUS
also continually examines emerging technologies in complementary or
related fields for further development and commercialization.
Additional information is available at www.ITUScorp.com.
Forward-Looking Statements: Statements that are
not historical fact may be considered forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements are not statements of
historical facts, but rather reflect ITUS Corporation's current
expectations concerning future events and results. We generally use
the words "believes," "expects," "intends," "plans," "anticipates,"
"likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We
undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law. You are
cautioned not to unduly rely on such forward-looking statements
when evaluating the information presented in this press
release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/itus-corporation-changing-company-name-to-anixa-biosciences-and-stock-ticker-symbol-to-anix-300720731.html
SOURCE ITUS Corporation